Increasing CAR Treg emphasis
TxCell’s new and novel CAR-modified regulatory T-cell (CAR Treg) platform has developed rapidly since June with three key academic collaborations aimed at progressing a range of indications including an important one aimed at controlling transplant rejection. CAR Treg trials may start from 2018. The Ovasave Crohn’s Phase IIb will now start in 2018, formerly H216, with faster manufacturing. We expect a cash inflow in H216 of €7m with forecast cash of €3.5m at year end after a cash burn of €12m.Txcell SA. TxCell SA is a France-based biotechnology company. It is engaged in the development of therapies to cure inflammatory and autoimmune diseases. The Company conducts medical research in anti-inflammatory immunotherapy. TxCell SA's technology is based on Tr1 T-regulatory cells which enable the regulation of the immune system. The Company's strategy aims at re-establishing this immunologic equilibrium by bringing regulatory T cells to the body. TxCell SA produces products which are used to treat Inflammatory Bowel Disease, primarily treatment resistant Crohns Disease (OvaSave), Inflammatory Joint Diseases, initially treatment resistant Rheumatoid Arthritis (TX-RAD) and Neurological Diseases, as well as targeting Multiple Sclerosis (TX-MSD).
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.